Kai Fu, M.D., Ph.D.

Department Affiliations
Co-Director, James O. Armitage Center for Hematological Malignancies Research
Director, International Relations Office, Fred & Pamela Buffett Cancer Center

Hematopathology, lymphoma research
Please visit Dr. Fu's lab webpage for more details on his research.

Education and Training
Pre-Med., Nan Kai University, Tianjin, China, 1982-1985
M.D., Tianjin Medical University, Tianjin, China, 1985-1990
Ph.D., University of Kansas School of Medicine, 1992-1997
Pathology Residency, University of Alabama at Birmingham, 1998-2001
Surgical Pathology Fellowship, University of Alabama at Birmingham, 2001-2002
Hematopathology Fellowship, University of Nebraska Medical Center 2002-2004
Board certified in Anatomic and Clinical Pathology, 2002
Board certified in Hematology, 2004

Teaching Activities
Residents and Fellows: Hematopathology lectures, CPC conferences, journal club, and case reviews.

Notable Publications
G Lenz, G Wright, S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal, J Vose, M Bast, K Fu, DD Weisenburger, T Greiner, JO Armitage, A Kyle, L May, RD Gascoyne, JM Connors, G Troen, H Holte, S Kvaloy, D. Dierickx, G. Verhoef, J Delabie, EB Smeland, P Jares, A Martinez, A Lopez-Guillermo, E Montserrat, E Campo, RM Braziel, T Miller, LM Rimsza, J Cook, B Pohlman, J Sweetenham, R. Tubbs, RI Fisher, E Hartmann, A Rosenwald, G Ott, HK Muller-Hermelink, D Wrench, TA Lister, ES Jaffe, WH Wilson, WC Chan, LM Staudt. Molecular signatures of the tumor microenvironment predict survival in diffuse large B-cell lymphoma treated with chemotherapy plus rituximab. NEJM 2008.

Fu K, Weisenburger DD, Choi, WWL, Perry KD, Smith LM, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM. Addition of Rituximab to CHOP improves the survival of patients in both the GCB and non- GCB subgroups of diffuse large B-cell lymphoma. J Clin Oncol 2008 Jul 28.

Iqbal J. d'Amore F, Hu Q, Chan WC and Fu K. Gene Arrays in Lymphoma: Where will they fit in? Current Hematologic Malignancy Reports I: 129-136, 2006.

Dave SS, Fu K, Wright GE, Lam LT, Greiner TC, Weisenburger DD, Kluin P, Boerma EJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Vose J, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, for the Leukemia Lymphoma Molecular Profiling Project. Molecular Diagnosis of Burkitt Lymphoma. NEJM Jun 8; 354(23):2431-42, 2006.

Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC, Vose JM, Fu K, Armitage JO, Braziel RM, Campo E, Delabie J, Gascoyne RD, Jaffe ES, Muller-Hermelink HK, Ott G, Rosenwald A, Staudt LM, Im MY, Karaman MW, Pike BL, Chan WC, Hacia JG. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A Feb 14;103(7):2352-7, 2006.

Fu, K*, Weisenburger, DD, Greiner, TC, Dave, S, Wright, G, Rosenwald, A, Chiorazzi, M, Iqbal, J, Gesk, S, Siebert, R, DeJong, D, Jaffe, ES, Wilson, WH, Delabie, J, Ott, G, Dave, BJ, Sanger, WG, Smith, LM, Braziel, RM, Müller-Hermelink, HK, Campo, E, Gascoyne, RD, Staudt, LM, and Chan, WC. Cyclin D1-negative Mantle Cell Lymphoma: A Clinicopathological Study Based on Gene Expression Profiling. Blood 106(13):4315-21, 2005. *Corresponding author. 

For a detailed list of publications, click here.